Revealing tumor immunity after hematopoietic stem cell transplantation.
Allogeneic hematopoietic stem cell transplantation is currently the most effective method for inducing tumor immunity. However, the diversity of target antigens recognized by donor T cells has not been established. New studies show that tumor-reactive T cells are directed against diverse tumor-specific targets as well as minor histocompatibility antigens.
Wu
Catherine J
CJ
Cancer Vaccine Center, Dana-Farber Cancer Institute, Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Ritz
Jerome
J
D000818:Animals; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D006086:Graft vs Host Disease / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000276:immunology* / Q000601:surgery*; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology; D018448:Models, Immunological; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014184:Transplantation, Homologous; D016896:Treatment Outcome